Harandi AM - Search Results

1

Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP.

Vianello E, Persson J, Andersson B, van Veen S, Dias TL, Santoro F, Östensson M, Obudulu O, Agbajogu C, Torkzadeh S; VSV-EBOVAC; VSV-EBOPLUS Consortia; Nakaya HI, Medaglini D, Siegrist CA, Ottenhoff THM, Harandi AM. Vianello E, et al. Among authors: harandi am. iScience. 2023 Nov 23;26(12):108574. doi: 10.1016/j.isci.2023.108574. eCollection 2023 Dec 15. iScience. 2023. PMID: 38162033 Free PMC article.

2

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.

Holmgren J, Harandi AM, Czerkinsky C. Holmgren J, et al. Among authors: harandi am. Expert Rev Vaccines. 2003 Apr;2(2):205-17. doi: 10.1586/14760584.2.2.205. Expert Rev Vaccines. 2003. PMID: 12899572 Review.

3

CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.

Harandi AM, Holmgren J. Harandi AM, et al. Curr Opin Investig Drugs. 2004 Feb;5(2):141-5. Curr Opin Investig Drugs. 2004. PMID: 15043387 Review.

4

Recent developments in mucosal immunomodulatory adjuvants.

Harandi AM, Sanchez J, Eriksson K, Holmgren J. Harandi AM, et al. Curr Opin Investig Drugs. 2003 Feb;4(2):156-61. Curr Opin Investig Drugs. 2003. PMID: 12669375 Review.

5

Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice.

Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Harandi AM, et al. J Gen Virol. 2001 Apr;82(Pt 4):845-853. doi: 10.1099/0022-1317-82-4-845. J Gen Virol. 2001. PMID: 11257190

6

The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges.

Harandi AM. Harandi AM. J Clin Virol. 2004 Jul;30(3):207-10. doi: 10.1016/j.jcv.2004.03.001. J Clin Virol. 2004. PMID: 15135735 Review.

7

4th International Workshop in Vaccine Adjuvants and Parasitic Vaccines (adjuvant 2008).

Pérez O, Harandi AM. Pérez O, et al. Among authors: harandi am. Expert Rev Vaccines. 2008 Oct;7(8):1151-3. doi: 10.1586/14760584.7.8.1151. Expert Rev Vaccines. 2008. PMID: 18844589

8

Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Harandi AM, et al. J Virol. 2001 Jul;75(14):6705-9. doi: 10.1128/JVI.75.14.6705-6709.2001. J Virol. 2001. PMID: 11413339 Free PMC article.

9

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.

Lindqvist M, Persson J, Thörn K, Harandi AM. Lindqvist M, et al. Among authors: harandi am. J Immunol. 2009 May 15;182(10):6435-43. doi: 10.4049/jimmunol.0900136. J Immunol. 2009. PMID: 19414797

10

Mucosal adjuvants.

Harandi AM, Medaglini D. Harandi AM, et al. Curr HIV Res. 2010 Jun;8(4):330-5. doi: 10.2174/157016210791208695. Curr HIV Res. 2010. PMID: 20353395 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page